Company Filing History:
20 out of 37 
5 out of 5 
4 out of 67 Years Active: 2008-2023
Title: Innovations and Contributions of Jörg Kaufmann in RNA Technology
Introduction
Jörg Kaufmann, based in Berlin, Germany, is a prolific inventor with a remarkable portfolio of 24 patents. His work is primarily focused on the advancements in ribonucleic acid (RNA) technology, which holds significant implications in the field of molecular biology and therapeutics.
Latest Patents
Among his latest patents are innovations related to interfering RNA molecules. These inventions involve ribonucleic acid structures that feature a double-stranded configuration. The first strand of Kaufmann's designs contains a sequence of contiguous nucleotides that is at least partially complementary to a target nucleic acid. Simultaneously, the second strand reflects a stretch of contiguous nucleotides that are at least partially identical to the target. These double-stranded structures are explicitly designed to be blunt-ended, showcasing an advanced understanding of RNA design and functionality.
Career Highlights
Throughout his career, Jörg Kaufmann has been associated with notable companies in the biotechnology sector, including Silence Therapeutics GmbH and Silence Therapeutics Aktiengesellschaft. His contributions have been instrumental in pushing the boundaries of RNA-based therapies, impacting research and development in genetic regulation.
Collaborations
Kaufmann has worked alongside esteemed colleagues, including Anke Klippel-Giese and Klaus Giese. These collaborations have fostered innovation and growth in his projects, amplifying the effectiveness and reach of his contributions to RNA technology.
Conclusion
Jörg Kaufmann’s inventive spirit and significant number of patents reflect his dedication to advancing RNA technology. His work not only enhances the scientific community's understanding of molecular biology but also paves the way for novel therapeutic approaches, showcasing the vital role of inventors in shaping the future of medicine.